Oculis (NASDAQ:OCS) SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts. This geographic footprint supports both preclinical studies and multiple clinical trial sites, enabling the company to advance its lead candidates through Phase 1 and Phase 2 studies. Oculis collaborates with academic institutions, ophthalmology clinics and contract research organizations to evaluate safety, tolerability and efficacy in patient populations afflicted by retinal vascular disorders and neuro-ophthalmic conditions.
Under the leadership of Chief Executive Officer Rémi Barone, PhD, Oculis has secured strategic partnerships and grant funding to accelerate its programs. The management team combines expertise in ophthalmology, drug delivery and clinical development, reflecting a track record of successful product approvals in the eye-care space. By focusing on noninvasive delivery methods, Oculis seeks to address unmet needs in ophthalmic care, improve patient compliance and reduce treatment burdens associated with current injectable therapies.
As a publicly traded company on the Nasdaq Global Market, Oculis continues to advance its pipeline toward pivotal clinical trials, with the goal of bringing innovative, patient-friendly ophthalmic treatments to market in the coming years. The company remains committed to rigorous scientific research and regulatory engagement to support the potential approval of its lead candidates across major markets in North America and Europe.
